| Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer … C Schuhmacher, S Gretschel, F Lordick, P Reichardt, W Hohenberger, ... Journal of clinical oncology 28 (35), 5210-5218, 2010 | 889 | 2010 |
| Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10 C Pepe, B Hasan, TL Winton, L Seymour, B Graham, RB Livingston, ... Journal of clinical oncology 25 (12), 1553-1561, 2007 | 282 | 2007 |
| Definition of synchronous oligometastatic non–small cell lung cancer—a consensus report AMC Dingemans, LEL Hendriks, T Berghmans, A Levy, B Hasan, ... Journal of Thoracic Oncology 14 (12), 2109-2119, 2019 | 275 | 2019 |
| Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial PE Van Schil, P Baas, R Gaafar, AP Maat, M Van de Pol, B Hasan, ... European Respiratory Journal 36 (6), 1362-1369, 2010 | 269 | 2010 |
| Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis … R Dummer, P Quaglino, JC Becker, B Hasan, M Karrasch, S Whittaker, ... Journal of clinical oncology 30 (33), 4091-4097, 2012 | 129 | 2012 |
| A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based … RM Gaafar, VF Surmont, GV Scagliotti, RJ Van Klaveren, D Papamichael, ... European Journal of Cancer 47 (15), 2331-2340, 2011 | 120 | 2011 |
| Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis D De Ruysscher, B Lueza, C Le Péchoux, DH Johnson, M O'Brien, ... Annals of Oncology 27 (10), 1818-1828, 2016 | 117 | 2016 |
| Efficacy and safety of bexarotene combined with psoralen–ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB–IIA mycosis fungoides: final results from the EORTC … S Whittaker, P Ortiz, R Dummer, A Ranki, B Hasan, B Meulemans, ... British Journal of Dermatology 167 (3), 678-687, 2012 | 114 | 2012 |
| New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response J Menis, B Hasan, B Besse European Respiratory Review 23 (133), 367-378, 2014 | 107 | 2014 |
| Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials LK Hicks, MC Cheung, K Ding, B Hasan, L Seymour, A Le Maître, ... Cancer 115 (23), 5516-5525, 2009 | 102 | 2009 |
| The APPLE trial: feasibility and activity of AZD9291 (osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613 J Remon, J Menis, B Hasan, A Peric, E De Maio, S Novello, M Reck, ... Clinical lung cancer 18 (5), 583-588, 2017 | 100 | 2017 |
| Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung … A Levy, C Faivre-Finn, B Hasan, E De Maio, AS Berghoff, N Girard, ... European Journal of Cancer 93, 37-46, 2018 | 73 | 2018 |
| Defining synchronous oligometastatic non–small cell lung cancer: a systematic review N Giaj-Levra, M Giaj-Levra, V Durieux, S Novello, B Besse, B Hasan, ... Journal of Thoracic Oncology 14 (12), 2053-2061, 2019 | 70 | 2019 |
| Attitudes and referral patterns of lung cancer specialists in Europe to Specialized Palliative Care (SPC) and the practice of Early Palliative Care (EPC) H Charalambous, A Pallis, B Hasan, M O’Brien BMC palliative care 13, 1-7, 2014 | 70 | 2014 |
| Biomarkers for malignant pleural mesothelioma: current status L Greillier, P Baas, JJ Welch, B Hasan, A Passioukov Molecular Diagnosis & Therapy 12, 375-390, 2008 | 69 | 2008 |
| A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR. 21 M Florescu, B Hasan, L Seymour, K Ding, FA Shepherd Journal of Thoracic Oncology 3 (6), 590-598, 2008 | 60 | 2008 |
| Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for … MER O’Brien, RM Gaafar, S Popat, F Grossi, A Price, DC Talbot, T Cufer, ... European journal of cancer 49 (13), 2815-2822, 2013 | 55 | 2013 |
| Economic Analysis of NCIC CTG JBR. 10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report … R Ng, B Hasan, N Mittmann, M Florescu, FA Shepherd, K Ding, CA Butts, ... Journal of clinical oncology 25 (16), 2256-2261, 2007 | 54 | 2007 |
| EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease A Levy, LEL Hendriks, T Berghmans, C Faivre-Finn, M GiajLevra, ... European journal of cancer 122, 109-114, 2019 | 49 | 2019 |
| A randomized open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: the European Thoracic Oncology Platform (ETOP … S Peters, S Danson, B Hasan, U Dafni, N Reinmuth, M Majem, ... Journal of Thoracic Oncology 15 (10), 1647-1656, 2020 | 46 | 2020 |
Jan P van MeerbeeckUniversiteit Antwerpen - Universitair Ziekenhuis Antwerpen- Universiteit GentPatvirtintas el. paštas uza.be